Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Jun 27, 2025; 17(6): 106276
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106276
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106276
Table 3 Comorbidities analysis
| Comorbidity | Infection group (n = 20) (%) | Non-infection group (n = 57) (%) | P value |
| Diabetes mellitus | 45 (9/20) | 22.8 (13/57) | < 0.05 |
| Hypertension | 35 (7/20) | 31.6 (18/57) | > 0.05 |
| Cardiovascular disease | 20 (4/20) | 17.5 (10/57) | > 0.05 |
| Chronic kidney disease | 15 (3/20) | 12.3 (7/57) | > 0.05 |
| Chronic lung disease | 10 (2/20) | 8.8 (5/57) | > 0.05 |
| Obesity | 25 (5/20) | 17.5 (10/57) | > 0.05 |
| Hyperlipidemia | 30 (6/20) | 26.3 (15/57) | > 0.05 |
| History of stroke | 10 (2/20) | 8.8 (5/57) | > 0.05 |
| History of cancer | 5 (1/20) | 3.5 (2/57) | > 0.05 |
- Citation: Wang G, Qi R. Analysis of risk factors for post-operative infection following drug-eluting trans arterial chemo embolization in hepatocellular carcinoma: A retrospective study. World J Gastrointest Surg 2025; 17(6): 106276
- URL: https://www.wjgnet.com/1948-9366/full/v17/i6/106276.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i6.106276